Page last updated: 2024-11-11

rmp 7

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

RMP 7: a synthetic bradykinin analog; selectively increases uptake of molecular tracers in RG2 glial tumors [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID6918284
CHEMBL ID2105864
SCHEMBL ID411837
MeSH IDM0237580

Synonyms (31)

Synonym
gtpl672
[hyp3,thi5,4-me-tyr8psi(ch2-nh)arg9]bradykinin
labradimil
rmp-7
cereport
lobradimil
159768-75-9
(2s)-2-[[(2s)-2-[[(2s)-1-[(2s)-2-[[(2s)-2-[[2-[[(2s,4r)-1-[(2s)-1-[(2s)-2-amino-5-(diaminomethylideneamino)pentanoyl]pyrrolidine-2-carbonyl]-4-hydroxypyrrolidine-2-carbonyl]amino]acetyl]amino]-3-thiophen-2-ylpropanoyl]amino]-3-hydroxypropanoyl]pyrrolidine
rmp 7
CHEMBL2105864
l-prolinamide, l-arginyl-l-prolyl-trans-4-hydroxy-l-prolyl-3-(2-thienyl)-l-alanylglycyl-l-seryl-n-(2-((4-((aminoiminomethyl)amino)-1-carboxybutyl)amino)-1-((4-methoxyphenyl)methyl)ethyl)-, (s-(r*,r*))-
labradimil [usan:inn]
2mk663c346 ,
bradykinin, 3-(trans-4-hydroxy-l-proline)-5-(3-(2-thienyl)-l-alanine)-8-de-l-phenylalanine-9-(n2-(2-amino-3-(4-methoxyphenyl)propyl)-l-arginine)-, (s)-
n2-((s)-2-(l-arginyl-l-prolyl-trans-4-hydroxy-l-prolylglycyl-3-(2-thienyl)-l-alanyl-l-seryl-l-prolinamido)-3-(p-methoxyphenyl)propyl)-l-arginine
(s-(r*,r*))-l-arginyl-l-prolyl-trans-4-hydroxy-l-prolyl-3-(2-thienyl)-l-alanylglycyl-l-seryl-n-(2-((4-((aminoiminomethyl)amino)-1-carboxybutyl)amino)-1-((4-methoxyphenyl)methyl)ethyl)-l-prolinamide
n(sup 2)-((s)-2-(l-arginyl-l-prolyl-trans-4-hydroxy-l-prolyglycyl-3-(2-thienyl)-l-alanyl-l-seryl-l-prolinamido)-3-(p-methoxyphenyl)propyl)-l-arginine
(s-(r*,r*))-l-arginyl-l-prolyl-trans-4-hydroxy-l-prolylglycyl-3-(2-thienyl)-l-alanyl-l-seryl-n-(2-((4-(aminoiminomethyl)amino)-1-carboxybutyl)amino)-1-((4-methoxyphenyl)methyl)ethyl)-l-prolinamide
l-arginine, l-arginyl-l-prolyl-(4r)-4-hydroxy-l-prolyl-3-(2-thienyl)-l-alanylglycyl-l-seryl-l-prolyl-o-methyl-l-tyrosyl-psi(ch2-nh)-
drg-0182
unii-2mk663c346
SCHEMBL411837
173220-35-4
labradimil [inn]
labradimil [usan]
n(sup 2)2-((s)-2-(l-arginyl-l-prolyl-trans-4-hydroxy-l-prolyglycyl-3-(2-thienyl)-l-alanyl-l-seryl-l-prolinamido)-3-(p-methoxyphenyl)propyl)-l-arginine
DB06549
Q27078449
HY-105155
CS-0025139
AKOS040748717

Research Excerpts

Toxicity

ExcerptReferenceRelevance
" The safer and effective administration of lower doses of CsA combined with enhanced BBB permeability using Cereport, offers a novel way of producing protective effects in the CNS without the toxic liabilities of high-dose CsA."( Bradykinin receptor agonist facilitates low-dose cyclosporine-A protection against 6-hydroxydopamine neurotoxicity.
Bartus, RT; Borlongan, CV; Emerich, DF; Hoffer, BJ, 2002
)
0.31

Pharmacokinetics

ExcerptReferenceRelevance
" Pharmacokinetic parameters for carboplatin were compared with respect to the dose of Cereport and with historical controls."( Pharmacokinetics of carboplatin administered in combination with the bradykinin agonist Cereport (RMP-7) for the treatment of brain tumours.
Bleehen, N; Boddy, AV; Calvert, AH; Ford, J; Lind, MJ; Thomas, HD, 2000
)
0.31
"Carboplatin pharmacokinetic studies were performed on 21 of 25 children with primary brain tumors who received carboplatin and lobradimil on two consecutive days every 28 days in a phase I dose-escalation trial of lobradimil."( Pharmacokinetics of carboplatin administered with lobradimil to pediatric patients with brain tumors.
Aikin, A; Balis, FM; Egorin, M; Gervais, A; Warren, K, 2004
)
0.32
" The degree to which the measured carboplatin AUC exceeded the target AUC appeared to be greater at higher doses of lobradimil, suggesting that the failure of the adaptive dosing method was related to an unexpected pharmacokinetic drug interaction."( Pharmacokinetics of carboplatin administered with lobradimil to pediatric patients with brain tumors.
Aikin, A; Balis, FM; Egorin, M; Gervais, A; Warren, K, 2004
)
0.32

Compound-Compound Interactions

ExcerptReferenceRelevance
" In order to investigate the pharmacokinetics of carboplatin in combination with Cereport, we performed pharmacological studies in conjunction with early clinical trials."( Pharmacokinetics of carboplatin administered in combination with the bradykinin agonist Cereport (RMP-7) for the treatment of brain tumours.
Bleehen, N; Boddy, AV; Calvert, AH; Ford, J; Lind, MJ; Thomas, HD, 2000
)
0.31
"Cereport combined with carboplatin was well-tolerated, with mild haematological toxicities consistent with the target area under the concentration time curve (AUC) of 7 mg/ml x min."( Pharmacokinetics of carboplatin administered in combination with the bradykinin agonist Cereport (RMP-7) for the treatment of brain tumours.
Bleehen, N; Boddy, AV; Calvert, AH; Ford, J; Lind, MJ; Thomas, HD, 2000
)
0.31
"To determine the pharmacokinetics of adaptively dosed carboplatin when administered in combination with the bradykinin agonist, lobradimil (RMP-7, Cereport), to pediatric patients with brain tumors."( Pharmacokinetics of carboplatin administered with lobradimil to pediatric patients with brain tumors.
Aikin, A; Balis, FM; Egorin, M; Gervais, A; Warren, K, 2004
)
0.32

Bioavailability

ExcerptReferenceRelevance
" Tight junction (TJ) modulation offers an approach to increase bioavailability of pharmaceutical compounds."( Recent progress in tight junction modulation for improving bioavailability.
Baumann, K; Reichl, S; Saaber, D; Wollenhaupt, S, 2014
)
0.4

Dosage Studied

ExcerptRelevanceReference
" dosing regimens included pre-treatment with RMP-7 (0."( Intravenous infusion of RMP-7 increases ocular uptake of ganciclovir.
Bartus, RT; Elliot, PJ; Mackic, JB; Zlokovic, BV, 1997
)
0.3
" For each subject, one of the alternating dosing sequences (above) was repeated four times during a single dosing session which lasted approximately 40 minutes."( Intra-arterial administration of carboplatin and the blood brain barrier permeabilizing agent, RMP-7: a toxicologic evaluation in swine.
Bartus, RT; Black, KL; Gobin, YP; Kim, NN; LeBel, CP; Riley, MG; Watson, VE, 1998
)
0.3
" A high dosage (100 mg of GCV/kg/day) eradicated all HSV-tk- and HSV-tk+ tumors."( Intravenous RMP-7 increases delivery of ganciclovir into rat brain tumors and enhances the effects of herpes simplex virus thymidine kinase gene therapy.
Anderson, WF; Bartus, R; Gordon, EM; Gray, B; Jovanovic, S; Kittaka, M; LeMay, DR; McComb, JG; Stins, MF; Tabrizi, P; Weiss, MH; Zlokovic, BV, 1998
)
0.3
" Carboplatin dosing was by target area under the curve (AUC) according to the Calvert protocol."( A phase I study of intravenous RMP-7 with carboplatin in patients with progression of malignant glioma.
Barton, T; Bleehen, NM; Ford, J; Osborn, C, 1998
)
0.3
" Collectively, these data provide the first systematic evaluation of dosing parameters involving receptor-mediated changes in BBTB permeability and provide new information regarding the pharmacodynamics and potential clinical use of Cereport."( Enhanced delivery of carboplatin into brain tumours with intravenous Cereport (RMP-7): dramatic differences and insight gained from dosing parameters.
Agostino, M; Bartus, RT; Dean, R; Emerich, DF; Hasler, B; Kim, BS; Pink, M; Snodgrass, P; Xiong, H, 1999
)
0.3
" Neurological impairment, performance status and steroid use were measured prior to dosing at each cycle and tumour volume by 3-D MRI at the end of cycles 2, 4, 6, 9 and 12."( Phase II studies of RMP-7 and carboplatin in the treatment of recurrent high grade glioma. RMP-7 European Study Group.
Barton, T; Grant, R; Gregor, A; Hadley, DM; Lind, M; Newman, H; Osborn, C, 1999
)
0.3
" However, immunosuppressant side effects (including nephrotoxicity and hepatotoxicity) are associated with such CsA dosing regimens."( Bradykinin receptor agonist facilitates low-dose cyclosporine-A protection against 6-hydroxydopamine neurotoxicity.
Bartus, RT; Borlongan, CV; Emerich, DF; Hoffer, BJ, 2002
)
0.31
"To determine the pharmacokinetics of adaptively dosed carboplatin when administered in combination with the bradykinin agonist, lobradimil (RMP-7, Cereport), to pediatric patients with brain tumors."( Pharmacokinetics of carboplatin administered with lobradimil to pediatric patients with brain tumors.
Aikin, A; Balis, FM; Egorin, M; Gervais, A; Warren, K, 2004
)
0.32
" The adaptive dosing formula was: carboplatin dose (mg/m2)=target AUC (mg."( Pharmacokinetics of carboplatin administered with lobradimil to pediatric patients with brain tumors.
Aikin, A; Balis, FM; Egorin, M; Gervais, A; Warren, K, 2004
)
0.32
"Adaptive dosing of carboplatin based on GFR overestimated the dose required to achieve the target carboplatin AUC in pediatric patients with brain tumors treated with concurrent lobradimil."( Pharmacokinetics of carboplatin administered with lobradimil to pediatric patients with brain tumors.
Aikin, A; Balis, FM; Egorin, M; Gervais, A; Warren, K, 2004
)
0.32
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Protein Targets (1)

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
B2 bradykinin receptorHomo sapiens (human)Ki0.01900.00000.70577.6740AID43286
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (16)

Processvia Protein(s)Taxonomy
smooth muscle contractionB2 bradykinin receptorHomo sapiens (human)
inflammatory responseB2 bradykinin receptorHomo sapiens (human)
cell surface receptor signaling pathwayB2 bradykinin receptorHomo sapiens (human)
cell surface receptor protein tyrosine kinase signaling pathwayB2 bradykinin receptorHomo sapiens (human)
positive regulation of cytosolic calcium ion concentrationB2 bradykinin receptorHomo sapiens (human)
blood circulationB2 bradykinin receptorHomo sapiens (human)
response to salt stressB2 bradykinin receptorHomo sapiens (human)
regulation of vasoconstrictionB2 bradykinin receptorHomo sapiens (human)
negative regulation of peptidyl-serine phosphorylationB2 bradykinin receptorHomo sapiens (human)
vasoconstrictionB2 bradykinin receptorHomo sapiens (human)
vasodilationB2 bradykinin receptorHomo sapiens (human)
regulation of vascular permeabilityB2 bradykinin receptorHomo sapiens (human)
arachidonic acid secretionB2 bradykinin receptorHomo sapiens (human)
negative regulation of intrinsic apoptotic signaling pathway in response to osmotic stress by p53 class mediatorB2 bradykinin receptorHomo sapiens (human)
intrinsic apoptotic signaling pathway in response to osmotic stress by p53 class mediatorB2 bradykinin receptorHomo sapiens (human)
G protein-coupled receptor signaling pathwayB2 bradykinin receptorHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (6)

Processvia Protein(s)Taxonomy
protease bindingB2 bradykinin receptorHomo sapiens (human)
phosphatidylinositol phospholipase C activityB2 bradykinin receptorHomo sapiens (human)
bradykinin receptor activityB2 bradykinin receptorHomo sapiens (human)
protein bindingB2 bradykinin receptorHomo sapiens (human)
type 1 angiotensin receptor bindingB2 bradykinin receptorHomo sapiens (human)
protein heterodimerization activityB2 bradykinin receptorHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (4)

Processvia Protein(s)Taxonomy
endosomeB2 bradykinin receptorHomo sapiens (human)
Golgi apparatusB2 bradykinin receptorHomo sapiens (human)
plasma membraneB2 bradykinin receptorHomo sapiens (human)
intracellular membrane-bounded organelleB2 bradykinin receptorHomo sapiens (human)
plasma membraneB2 bradykinin receptorHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (5)

Assay IDTitleYearJournalArticle
AID1347008Rat B2 receptor (Bradykinin receptors)1999Journal of medicinal chemistry, Oct-07, Volume: 42, Issue:20
Design and synthesis of potent bradykinin agonists containing a benzothiazepine moiety.
AID1347008Rat B2 receptor (Bradykinin receptors)1994The Journal of pharmacology and experimental therapeutics, Oct, Volume: 271, Issue:1
The bradykinin analog RMP-7 increases intracellular free calcium levels in rat brain microvascular endothelial cells.
AID92692Agonistic activity on human umbilical vein(HUV) in presence of inhibitors1999Journal of medicinal chemistry, Oct-07, Volume: 42, Issue:20
Design and synthesis of potent bradykinin agonists containing a benzothiazepine moiety.
AID43286Binding affinity against human cloned Bradykinin receptor B2 expressed in CHO cells using [3H]-bradykinin as radioligand1999Journal of medicinal chemistry, Oct-07, Volume: 42, Issue:20
Design and synthesis of potent bradykinin agonists containing a benzothiazepine moiety.
AID92588Agonistic activity on human umbilical vein(HUV) in absence of inhibitors1999Journal of medicinal chemistry, Oct-07, Volume: 42, Issue:20
Design and synthesis of potent bradykinin agonists containing a benzothiazepine moiety.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (65)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's33 (50.77)18.2507
2000's28 (43.08)29.6817
2010's4 (6.15)24.3611
2020's0 (0.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 17.41

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index17.41 (24.57)
Research Supply Index4.39 (2.92)
Research Growth Index4.18 (4.65)
Search Engine Demand Index15.26 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (17.41)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials12 (17.65%)5.53%
Reviews3 (4.41%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other53 (77.94%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]